Cargando…

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

BACKGROUND: Identifying patients with metastatic colorectal cancer who will have an early disease progression during induction chemotherapy (IC) and identifying patients who may have a chemotherapy-free interval (CFI) after IC are two major challenges. METHODS: A logistic model was used to identify...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aparicio, Thomas, Bennouna, Jaafar, Le Malicot, Karine, Boige, Valérie, Taieb, Julien, Bouché, Olivier, Phelip, Jean-Marc, François, Eric, Borel, Christian, Faroux, Roger, Dahan, Laetitia, Bachet, Jean-Baptiste, Egreteau, Joelle, Kaminsky, Marie-Christine, Gornet, Jean-Marc, Cojocarasu, Oana, Gasmi, Mohamed, Guerin-Meyer, Véronique, Lepage, Côme, Ghiringhelli, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109054/ https://www.ncbi.nlm.nih.gov/pubmed/32015513 http://dx.doi.org/10.1038/s41416-020-0735-8

Ejemplares similares

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial
por: de Rauglaudre, Bernadette, et al.
Publicado: (2022)

Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma
por: Canton, Clémence, et al.
Publicado: (2022)

Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study
por: Reichling, Cynthia, et al.
Publicado: (2020)

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results
por: Aparicio, T, et al.
Publicado: (2018)

Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59
por: Evrard, Camille, et al.
Publicado: (2022)

Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
por: Assenat, Eric, et al.
Publicado: (2019)

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
por: Schwarz, Lilian, et al.
Publicado: (2018)

Les prodiges : piéce en deux parties /
por: Vauthier, Jean
Publicado: (1958)

Correction to: Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
por: Schwarz, Lilian, et al.
Publicado: (2020)

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial
por: Taïeb, Julien, et al.
Publicado: (2023)

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial
por: Bidard, François-Clément, et al.
Publicado: (2019)

Bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with unresectable peritoneal metastasis from gastric cancer: the first study in Western countries
por: Lo Dico, Rea, et al.
Publicado: (2020)

The prodigal son
por: Britten, Benjamin, 1913-1976
Publicado: (1990)

Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy – a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol
por: Boilève, Alice, et al.
Publicado: (2020)

Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas – PRODIGE 19 – FFCD1103 – ADCI002
por: Piessen, Guillaume, et al.
Publicado: (2013)

Cilia - the prodigal organelle
por: Beales, Phil, et al.
Publicado: (2012)

Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer
por: Grancher, Adrien, et al.
Publicado: (2022)

Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 - ECKINOXE trial
por: Karoui, Mehdi, et al.
Publicado: (2015)

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)
por: Kim, Stefano, et al.
Publicado: (2017)

The return of the prodigal Goldstone boson
por: Kapusta, Joseph I., et al.
Publicado: (1995)

The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer
por: Le Corre, Delphine, et al.
Publicado: (2019)

Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy
por: Fumet, Jean-David, et al.
Publicado: (2020)

Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)
por: Dahan, Laetitia, et al.
Publicado: (2010)

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
por: Kim, Stefano, et al.
Publicado: (2023)

Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
por: Marisa, Laetitia, et al.
Publicado: (2021)

COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)
por: Di Fiore, Frederic, et al.
Publicado: (2020)

ProDiGe: Prioritization Of Disease Genes with multitask machine learning from positive and unlabeled examples
por: Mordelet, Fantine, et al.
Publicado: (2011)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
por: Lièvre, Astrid, et al.
Publicado: (2009)

Prodigal: prokaryotic gene recognition and translation initiation site identification
por: Hyatt, Doug, et al.
Publicado: (2010)

NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)
por: Brouquet, Antoine, et al.
Publicado: (2020)

Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307)
por: Nuemi, Gillles, et al.
Publicado: (2015)

Intensification of induction chemotherapy before consolidation chemoradiotherapy improves progression-free survival and time without treatment in patients with locally advanced pancreatic cancers
por: Williet, Nicolas, et al.
Publicado: (2018)

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
por: Thibaudin, Marion, et al.
Publicado: (2023)

Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors
por: Bachet, Jean-Baptiste, et al.
Publicado: (2010)

A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy‐Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2021)

Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma
por: Gras, Pauline, et al.
Publicado: (2012)

Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study
por: Bachet, Jean-Baptiste, et al.
Publicado: (2020)

Histopathological and molecular study from EUS fine-needle biopsy of a programmed cell death ligand 1 positive, KRAS mutated pancreatic metastasis
por: Tournier, Quentin, et al.
Publicado: (2020)

The prodigal tongue: the love-hate relationship between British and American English
por: Murphy, Lynne
Publicado: (2018)

Growth rate evolution in improved environments under Prodigal Son dynamics
por: Collins, Sinéad
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j5mjtrf11poujhqg37s21q4ekq